AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

What happened: AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 INTREPID trial of lutikizumab, an investigational IL-1α/IL-1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa. Key numbers: HiSCR75 at Week 16 was Why it matters: INTREPID is described as the first Phase 3 study including adults and adolescents with HS to show statistically significant HiSCR75 rates at Week 16 as the primary endpoint. Data from a 36-week blinded extension are expected in 2027 and will support regulatory submissions in the second half of the year. Market: -1.5% today ($284.80), +26.2% YTD, 0.9x vol — as of 13:15 UTC

AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 INTREPID trial of lutikizumab, an investigational IL-1α/IL-1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa.

INTREPID is described as the first Phase 3 study including adults and adolescents with HS to show statistically significant HiSCR75 rates at Week 16 as the primary endpoint. Data from a 36-week blinded extension are expected in 2027 and will support regulatory submissions in the second half of the year. Market: -1.5% today ($284.80), +26.2% YTD, 0.9x vol — as of 13:15 UTC